RICTOR Amplification

CI-VAR-00000217Explore in graph →CIViC 573

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastric Adenocarcinoma1
RICTOR Amplification	Vistusertib	Predictive	D	Supports Sensitivity Response	3	submitted	EID1915 Tumor samples from 640 patients with metastatic solid tumors were prospectively analyzed with a next-generation sequencing assay to identify molecular targets. 13 (2%) of 640 patients had a RICTOR-aam… (full text at CIViC) PMID 28028034 · Kim et al., 2017 · Open in CIViC	civic
Lung Adenocarcinoma1
RICTOR Amplification	Onatasertib + SapanisertibSubstitutes	Predictive	C	Supports Sensitivity Response	2	accepted	EID1440 Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alterat…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Small Cell Carcinoma2
RICTOR Amplification	Vistusertib	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID7449 In a phase 2 basket trial, patients with small-cell lung carcinoma (SLC) who failed platinum-based chemotherapy and harbored RICTOR amplification were treated with mTOR 1/2 inhibitor vistusertib (AZD2… (full text at CIViC) Open in CIViC	civic
RICTOR Amplification	MTOR Kinase Inhibitor AZD8055 + Sapanisertib + VistusertibSubstitutes	Predictive	D	Supports Sensitivity Response	2	submitted	EID1916 RICTOR amplification was observed in ca. 14% of 42 SCLC patients with panel sequencing results. 4 cell lines (2 with RICTOR CN gain, 2 without) were tested for the efficacy of mTOR pathway inhibitors.… (full text at CIViC) PMID 27863413 · Sakre et al., 2017 · Open in CIViC	civic